CCA
PRVB

Column Capital Advisors’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Column Capital Advisors’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-152
Closed -$1K – 839
2021
Q3 		$1K Buy
+152
New +$977 ﹤0.01% 719

Other funds holding PRVB

SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Column Capital Advisors's PRVB Position: Q4 2021 in Review

Column Capital Advisors sold out of Provention Bio, Inc. Common Stock (PRVB) in Q4 2021, closing a stake of 152 shares — an estimated $1K sold.

Column Capital Advisors first reported a position in PRVB in Q3 2021 and held it in 1 quarter. The position peaked at $1K in Q3 2021. 112 funds tracked by Wall St. Rank hold PRVB as of Q4 2021.

  • Column Capital Advisors reported no remaining Provention Bio, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Column Capital Advisors sold 152 Provention Bio, Inc. Common Stock shares in Q4 2021, an estimated $1K.
  • Column Capital Advisors first reported a position in Provention Bio, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Column Capital Advisors's Provention Bio, Inc. Common Stock position peaked at $1K in Q3 2021.
  • 112 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q4 2021.

Based on Column Capital Advisors's 13F filing for Q4 2021, filed 7 Feb 2022.